公式財務諸表に基づく売上高、利益、キャッシュフローの推移。
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
インタラクティブチャートと全財務諸表を見る → バリュエーションモデル（DCF）→
| 損益計算書 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 売上高合計 | $874M | $944M | $705M | $788M | $587M | $810M | $729M | $1.1B | $600M | $514M | $347M | $284M | $214M | $147M | $102M | $99M | $108M | $122M | $107M | $58M | $15M |
| 売上総利益 | $857M | $928M | $694M | $779M | $573M | $800M | $717M | $1.1B | $598M | $514M | $2M | ($39M) | ($28M) | ($37M) | ($56M) | $99M | $108M | $122M | $107M | $70M | $25M |
| 売上総利益率 % | 98.0% | 98.3% | 98.4% | 98.8% | 97.6% | 98.7% | 98.4% | 99.6% | 99.7% | 100.0% | 0.7% | -13.6% | -12.9% | -24.9% | -55.3% | 100.0% | 100.0% | 100.0% | 100.0% | 119.3% | 165.1% |
| 営業利益（EBIT） | ($594M) | ($382M) | ($475M) | ($354M) | ($410M) | ($30M) | ($172M) | $366M | ($61M) | $31M | ($46M) | ($76M) | ($48M) | ($52M) | ($69M) | ($71M) | ($48M) | ($28M) | ($13M) | ($33M) | ($65M) |
| 営業利益率 % | -68.0% | -40.5% | -67.4% | -44.9% | -69.8% | -3.7% | -23.6% | 32.6% | -10.2% | 6.0% | -13.4% | -26.7% | -22.3% | -35.1% | -67.5% | -71.8% | -44.6% | -22.7% | -12.2% | -56.4% | -438.9% |
| 当期純利益 | ($566M) | ($381M) | ($454M) | ($366M) | ($270M) | ($29M) | ($487M) | $294M | $274M | $0M | ($87M) | ($88M) | ($39M) | ($61M) | ($65M) | ($85M) | ($61M) | $155M | ($18M) | ($11M) | ($46M) |
| 純利益率 % | -64.8% | -40.4% | -64.4% | -46.5% | -45.9% | -3.5% | -66.8% | 26.2% | 45.6% | 0.1% | -25.0% | -31.1% | -18.2% | -41.2% | -64.2% | -85.6% | -56.5% | 127.5% | -17.0% | -18.8% | -308.9% |
| EBITDA | — | ($287M) | ($354M) | ($236M) | ($228M) | ($5M) | ($155M) | $382M | ($19M) | $36M | ($37M) | ($41M) | ($23M) | ($42M) | ($43M) | ($56M) | ($39M) | ($16M) | $4M | ($26M) | ($59M) |
| 1株当たり利益（EPS） | $-3.46 | $-2.38 | $-3.04 | $-2.56 | $-1.90 | $-0.20 | $-3.49 | $2.06 | $2.04 | $0.00 | $-0.72 | $-0.74 | $-0.33 | $-0.55 | $-0.65 | $-0.85 | $-0.62 | $1.58 | $-0.19 | $-0.13 | $-0.62 |
| 発行済株式数（百万株） | — | 160M | 150M | 143M | 142M | 141M | 140M | 143M | 134M | 126M | 121M | 120M | 118M | 111M | 101M | 100M | 99M | 98M | 95M | 84M | 74M |
出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。
貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は IONS のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/IONS
本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。
About TickerBase · Data methodology & sources · Privacy · Terms